| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Previous issue > Previous issue



Table of Contents | June, 2022  Vol. 40  No.2 Previous Issue | Next Issue | Archive
In this issue:



Review Article
An overview of radiation-induced heart disease
Samer Ellahham, Amani Khalouf, Mohammed Elkhazendar, Nour Dababo, Yosef Manla
Radiat Oncol J. 2022;40(2):89-102.   Published online June 21, 2022
Radiation therapy (RT) has dramatically improved cancer survival, leading to several inevitable complications. Unintentional irradiation of the heart can lead to radiation-induced heart disease (RIHD), including cardiomyopathy, pericarditis, coronary artery disease, valvular heart disease, and conduction system abnormalities. Furthermore, the development of RIHD is aggravated with the addition of chemotherapy. The screening, diagnosis, and follow-up for RIHD in patients who...
Original Articles
Clinical Investigation
Improving locoregional outcome in high-intermediate-risk and high-risk stage I endometrial cancer with surgical staging followed by brachytherapy
Candan Demiroz Abakay, Sonay Arslan, Meral Kurt, Sibel Cetintas
Radiat Oncol J. 2022;40(2):103-110.   Published online May 25, 2022

Purpose: This study aims to assess the locoregional efficacy of postoperative vaginal brachytherapy (VBT) alone in patients undergoing surgical staging for early-stage high-intermediate-risk (HIR) and high-risk (HR) endometrial cancer. Materials and Methods: One hundred and four patients with early-stage HIR and HR endometrial cancer who underwent surgical staging were treated with adjuvant VBT alone. The patients with stage Ib, grade...
Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy
Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Lei Zheng, Jin He, Daniel A. Laheru, Ana De Jesus-Acosta, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang
Radiat Oncol J. 2022;40(2):111-119.   Published online May 20, 2022

Purpose: To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic cancer treated with anti-PD-1 (programmed cell death protein-1) antibody and SBRT. Materials and Methods: This was a retrospective review of 68 patients with borderline resectable or locally advanced pancreatic cancer treated with anti-PD-1 antibody and SBRT after multi-agent chemotherapy. Immunotherapy...
Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction
Tae Hoon Lee, Joo Ho Lee, Seong Keun Kwon, Eun-Jae Chung, Hong-Gyun Wu
Radiat Oncol J. 2022;40(2):120-126.   Published online May 17, 2022

Purpose: The purpose of this study was to evaluate the treatment outcomes and toxicity profile of patients with early glottic cancer who underwent hypofractionated radiation therapy (RT) with 3.5 Gy per fraction. Materials and Methods: A retrospective review was performed of the medical records of 35 patients with early stage (T1-2N0M0) glottic cancer who underwent definitive RT. The dose fractionation scheme...
Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study
Budhi Singh Yadav, Shipra Gupta, Divya Dahiya, Ankita Gupta, Arun Singh Oinam
Radiat Oncol J. 2022;40(2):127-140.   Published online June 20, 2022

Purpose: To assess the feasibility of accelerated hypofractionated radiotherapy with simultaneous integrated boost (SIB) in patients with breast cancer. Materials and Methods: A total of 27 patients after breast-conserving surgery were included in this study. Patients were planned on a four-dimensional computerized tomogram, and contouring was done using RTOG guidelines. The dose was 34 Gy/10#/2 week to the breast and 40...
Long-term oncological outcomes of hypofractionated versus conventional fractionated whole breast irradiation with simultaneous integrated boost in early-stage breast cancer
Chawalit Lertbutsayanukul, Manida Pitak, Chonnipa Nantavithya
Radiat Oncol J. 2022;40(2):141-150.   Published online May 20, 2022

Purpose: For patients with early breast cancer who undergo breast-conserving surgery, adjuvant whole breast irradiation (WBI) with simultaneous integrated boost (SIB) results in lower radiotherapy fractions. Published studies have shown that both conventional fraction with SIB (C-SIB) and hypofractionation with SIB (H-SIB) seem to be safe and feasible. In this study, we sought to compare the oncologic outcomes between C-SIB...
Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients
Christos Nanos, Vasilios Souftas, Athanasios Zissimopoulos, Michael I. Koukourakis
Radiat Oncol J. 2022;40(2):151-161.   Published online June 20, 2022

Purpose: Conventionally fractionated radiotherapy (CRT) is widely applied for the treatment of high-risk prostate cancer. Pelvic node irradiation improves control of the disease. Although the therapeutic guidelines support the use of hypofractionated and accelerated radiotherapy (HypoAR), this is addressed to prostate and seminal vesicles. At the same time, the safety and efficacy of HypoAR for pelvic node irradiation remain obscure. Material...
Case Report
Craniospinal irradiation for respiratory failure secondary to central nervous system Erdheim-Chester disease
Rahul N. Prasad, Peter J. Kobalka, Haley K. Perlow, Daniel M. Prevedello, Dukagjin M. Blakaj, Raju R. Raval, Joshua D. Palmer
Radiat Oncol J. 2022;40(2):162-168.   Published online May 20, 2022
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis typically featuring lower extremity osteosclerosis (96%) from Langerin-negative histiocytes with fibrosis. Central nervous system (CNS)-only disease is extremely rare, and particularly difficult to diagnose and manage. Neurologic complaints may be refractory to systemic therapy (ST), and the role of radiation therapy (RT) is undefined. We present a patient with ECD of...
E-Submission
Principles of Transparency and Best Practice
Author's Index
KOSRO
Journal Impact Factor 1.8
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Elekta Korea
DAWON MEDAX
Editorial Office
Department of Radiation Oncology, Samsung Medical Center,
Proton Therapy Center, B2, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
Tel : +82-2-3410-3617
E-mail: rojeditor@gmail.com, roj@kosro.or.kr
Copyright © The Korean Society for Radiation Oncology.                      Developed in M2PI
Close layer
prev next